You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Merck
Moodys
Boehringer Ingelheim
AstraZeneca

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Details for Patent: 10,322,139

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,322,139 protect, and when does it expire?

Patent 10,322,139 protects ZULRESSO and is included in one NDA.

This patent has thirty-two patent family members in twenty-two countries.

Summary for Patent: 10,322,139
Title:Neuroactive steroid formulations and methods of treating CNS disorders
Abstract: Formulations of comprising a neuroactive steroid, e.g., allopregnanolone; and optionally a cyclodextrin, e.g., a .beta.-cyclodextrin, e.g., a sulfo butyl ether .beta.-cyclodextrin, e.g., a .beta.-cyclodextrin, e.g., a sulfo butyl ether .beta.-cyclodextrin, e.g., CAPTISOL.RTM.; and methods of use in treating CNS disorders.
Inventor(s): Reddy; Kiran (Boston, MA)
Assignee: Sage Therapeutics, Inc. (Cambridge, MA)
Application Number:15/649,583
Patent Claim Types:
see list of patent claims
Composition; Dosage form;

Drugs Protected by US Patent 10,322,139

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sage Therap ZULRESSO brexanolone SOLUTION;INTRAVENOUS 211371-001 Jun 17, 2019 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,322,139

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2013212287   Start Trial
Australia 2018201307   Start Trial
Australia 2020217402   Start Trial
Canada 2862076   Start Trial
China 104736158   Start Trial
Denmark 2806877   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
McKesson
Express Scripts
Medtronic
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.